{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T20:43:08Z","timestamp":1759178588483},"reference-count":14,"publisher":"Hindawi Limited","issue":"1","license":[{"start":{"date-parts":[[2017,7,17]],"date-time":"2017-07-17T00:00:00Z","timestamp":1500249600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2017,7,17]],"date-time":"2017-07-17T00:00:00Z","timestamp":1500249600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pharm Ther"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1111\/jcpt.12589","type":"journal-article","created":{"date-parts":[[2017,7,18]],"date-time":"2017-07-18T04:12:36Z","timestamp":1500351156000},"page":"117-120","source":"Crossref","is-referenced-by-count":2,"title":["Long-acting formulation leading to severe long-term adverse effects: a case report of fluphenazine and persistent extrapyramidal symptoms"],"prefix":"10.1155","volume":"43","author":[{"given":"T.","family":"Omi","sequence":"first","affiliation":[{"name":"Department of Psychiatry; Osaka General Medical Center; Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Mitsui","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine; Osaka General Medical Center; Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Matsunaga","sequence":"additional","affiliation":[{"name":"Department of Psychiatry; Osaka General Medical Center; Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2017,7,17]]},"reference":[{"key":"10.1111\/jcpt.12589-BIB0001|jcpt12589-cit-0001","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1192\/bjp.195.52.s13","article-title":"Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review","volume":"52","author":"Taylor","year":"2009","journal-title":"Br J Psychiatry Suppl"},{"key":"10.1111\/jcpt.12589-BIB0002|jcpt12589-cit-0002","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1192\/bjp.179.4.290","article-title":"Systematic meta-review of depot antipsychotic drugs for people with schizophrenia","volume":"179","author":"Adams","year":"2001","journal-title":"Br J Psychiatry"},{"key":"10.1111\/jcpt.12589-BIB0003|jcpt12589-cit-0003","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/WNF.0b013e3182854f70","article-title":"Long-acting injectable antipsychotics and the development of postinjection delirium\/sedation syndrome (PDSS)","volume":"36","author":"Novakovic","year":"2013","journal-title":"Clin Neuropharmacol"},{"key":"10.1111\/jcpt.12589-BIB0004|jcpt12589-cit-0004","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/phar.1313","article-title":"Adverse effects associated with second-generation antipsychotic long-acting injection treatment: a comprehensive systematic review","volume":"33","author":"Gentile","year":"2013","journal-title":"Pharmacotherapy"},{"key":"10.1111\/jcpt.12589-BIB0005|jcpt12589-cit-0005","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1053\/j.ajkd.2010.05.014","article-title":"Management of poisonings:core curriculum","volume":"56","author":"Winchester","year":"2010","journal-title":"Am J Kidney"},{"key":"10.1111\/jcpt.12589-BIB0006|jcpt12589-cit-0006","first-page":"30327","article-title":"The possibility of the treatment for long-acting injectable antipsychotics induced severe side effects","volume":"S0735-6757","author":"Omi","year":"2017","journal-title":"Am J Emerg Med"},{"key":"10.1111\/jcpt.12589-BIB0007|jcpt12589-cit-0007","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF00431778","article-title":"Plasma levels of fluphenazine during fluphenazine decanoate treatment in schizophrenia","volume":"87","author":"Chang","year":"1985","journal-title":"Psychopharmacology"},{"key":"10.1111\/jcpt.12589-BIB0008|jcpt12589-cit-0008","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2710.1995.tb00629.x","article-title":"Monitoring plasma levels of fluphenazine during chronic therapy with fluphenazine decanoate","volume":"20","author":"Miller","year":"1995","journal-title":"J Clin Pharm Ther"},{"key":"10.1111\/jcpt.12589-BIB0009|jcpt12589-cit-0009","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/BF00433729","article-title":"A depot neuroleptic withdrawal study. Plasma concentration of fluphenazine and flupenthixol and relapse frequency","volume":"78","author":"Wistedt","year":"1982","journal-title":"Psychopharmacology"},{"key":"10.1111\/jcpt.12589-BIB0010|jcpt12589-cit-0010","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2165\/00002018-199920030-00006","article-title":"Managing antipsychotic-induced parkinsonism","volume":"20","author":"Mamo","year":"1999","journal-title":"MS Drug Saf"},{"key":"10.1111\/jcpt.12589-BIB0011|jcpt12589-cit-0011","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1007\/s00415-009-5039-0","article-title":"Clinical and [123I]FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism","volume":"256","author":"Tinazzi","year":"2009","journal-title":"J Neurol"},{"key":"10.1111\/jcpt.12589-BIB0012|jcpt12589-cit-0012","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1212\/01.wnl.0000302255.49113.51","article-title":"Understanding drug-induced parkinsonism: separating pearls from oysters","volume":"70","author":"Alvarez","year":"2008","journal-title":"Neurology"},{"key":"10.1111\/jcpt.12589-BIB0013|jcpt12589-cit-0013","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1002\/mds.23828","article-title":"Drug-induced parkinsonism: a review of 17\u00a0years\u2019 experience in a regional pharmacovigilance center in France","volume":"26","author":"Bondon-Guitton","year":"2011","journal-title":"Mov Disord"},{"key":"10.1111\/jcpt.12589-BIB0014|jcpt12589-cit-0014","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1176\/appi.ajp.2017.16091037","article-title":"KINECT 3: a phase 3 randomized, doubleblind, placebo-controlled trial of valbenazine for tardive dyskinesia","volume":"174","author":"Hauser","year":"2017","journal-title":"Am J Psychiatry"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12589","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jcpt.12589\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T18:03:09Z","timestamp":1671818589000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcpt.12589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,17]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"URL":"https:\/\/doi.org\/10.1111\/jcpt.12589","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7,17]]}}}